These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21710270)

  • 1. Assessing response in bone metastases in prostate cancer with diffusion weighted MRI.
    Messiou C; Collins DJ; Giles S; de Bono JS; Bianchini D; de Souza NM
    Eur Radiol; 2011 Oct; 21(10):2169-77. PubMed ID: 21710270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance.
    Morgan VA; Riches SF; Thomas K; Vanas N; Parker C; Giles S; Desouza NM
    Br J Radiol; 2011 Jan; 84(997):31-7. PubMed ID: 21172965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.
    Perez-Lopez R; Mateo J; Mossop H; Blackledge MD; Collins DJ; Rata M; Morgan VA; Macdonald A; Sandhu S; Lorente D; Rescigno P; Zafeiriou Z; Bianchini D; Porta N; Hall E; Leach MO; de Bono JS; Koh DM; Tunariu N
    Radiology; 2017 Apr; 283(1):168-177. PubMed ID: 27875103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps--initial observations.
    Reischauer C; Froehlich JM; Koh DM; Graf N; Padevit C; John H; Binkert CA; Boesiger P; Gutzeit A
    Radiology; 2010 Nov; 257(2):523-31. PubMed ID: 20829534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of prostate cancer lesions with high and with low Gleason score by diffusion-weighted MRI.
    Barbieri S; Brönnimann M; Boxler S; Vermathen P; Thoeny HC
    Eur Radiol; 2017 Apr; 27(4):1547-1555. PubMed ID: 27300199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance-guided focused ultrasound for the treatment of painful bone metastases: role of apparent diffusion coefficient (ADC) and dynamic contrast enhanced (DCE) MRI in the assessment of clinical outcome.
    Anzidei M; Napoli A; Sacconi B; Boni F; Noce V; Di Martino M; Saba L; Catalano C
    Radiol Med; 2016 Dec; 121(12):905-915. PubMed ID: 27567615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.
    Jacobs MA; Macura KJ; Zaheer A; Antonarakis ES; Stearns V; Wolff AC; Feiweier T; Kamel IR; Wahl RL; Pan L
    Acad Radiol; 2018 Nov; 25(11):1405-1414. PubMed ID: 29627288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffusion-weighted magnetic resonance imaging for early response assessment of chemoradiotherapy in patients with nasopharyngeal carcinoma.
    Chen Y; Liu X; Zheng D; Xu L; Hong L; Xu Y; Pan J
    Magn Reson Imaging; 2014 Jul; 32(6):630-7. PubMed ID: 24703576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apparent diffusion coefficient maps integrated in whole-body MRI examination for the evaluation of tumor response to chemotherapy in patients with multiple myeloma.
    Bonaffini PA; Ippolito D; Casiraghi A; Besostri V; Franzesi CT; Sironi S
    Acad Radiol; 2015 Sep; 22(9):1163-71. PubMed ID: 26182979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
    Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H
    AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion-weighted MRI of urinary bladder and prostate cancers.
    Kiliçkesmez O; Cimilli T; Inci E; Kayhan A; Bayramoğlu S; Taşdelen N; Gürmen N
    Diagn Interv Radiol; 2009 Jun; 15(2):104-10. PubMed ID: 19517380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of the apparent diffusion coefficient value of metastatic bone tumours on diffusion-weighted MRI images: differences according to the types of primary tumour, the affected bones, and clinical factors.
    Cha MJ; Yoon YC
    Clin Radiol; 2015 Oct; 70(10):1116-21. PubMed ID: 26145186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of granulocyte colony-stimulating factor on bone marrow: evaluation by intravoxel incoherent motion and dynamic contrast-enhanced magnetic resonance imaging.
    Minutoli F; Pergolizzi S; Blandino A; Mormina E; Amato E; Gaeta M
    Radiol Med; 2020 Mar; 125(3):280-287. PubMed ID: 31823293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI.
    Eiber M; Holzapfel K; Ganter C; Epple K; Metz S; Geinitz H; Kübler H; Gaa J; Rummeny EJ; Beer AJ
    J Magn Reson Imaging; 2011 May; 33(5):1160-70. PubMed ID: 21509875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffusion-Weighted MRI in the Assessment of Early Treatment Response in Patients with Squamous-Cell Carcinoma of the Head and Neck: Comparison with Morphological and PET/CT Findings.
    Martins EB; Chojniak R; Kowalski LP; Nicolau UR; Lima EN; Bitencourt AG
    PLoS One; 2015; 10(11):e0140009. PubMed ID: 26562784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing response of myeloma bone disease with diffusion-weighted MRI.
    Messiou C; Giles S; Collins DJ; West S; Davies FE; Morgan GJ; Desouza NM
    Br J Radiol; 2012 Dec; 85(1020):e1198-203. PubMed ID: 23175485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of diffusion weighted MR imaging as an early surrogate parameter for evaluation of tumor response to high-dose-rate brachytherapy of colorectal liver metastases.
    Wybranski C; Zeile M; Löwenthal D; Fischbach F; Pech M; Röhl FW; Gademann G; Ricke J; Dudeck O
    Radiat Oncol; 2011 Apr; 6(1):43. PubMed ID: 21524305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application value of diffusion weighted whole body imaging with background body signal suppression in monitoring the response to treatment of bone marrow involvement in lymphoma.
    Sun M; Cheng J; Zhang Y; Wang F; Meng Y; Fu X
    J Magn Reson Imaging; 2016 Dec; 44(6):1522-1529. PubMed ID: 27160047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of diffusion-weighted, intravoxel incoherent motion, and dynamic contrast-enhanced MR imaging in the assessment of response to radiotherapy of lytic bone metastases from breast cancer.
    Gaeta M; Benedetto C; Minutoli F; D'Angelo T; Amato E; Mazziotti S; Racchiusa S; Mormina E; Blandino A; Pergolizzi S
    Acad Radiol; 2014 Oct; 21(10):1286-93. PubMed ID: 25088834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.